TABLE 2.

Registered clinical trials on https://clinicaltrials.gov focused on microglia and Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis.

NCT number	Title	Status	Conditions	Study type	Interventions	Phase	Study completion date
NCT04840979	Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer’s Disease	Recruiting	Alzheimer’s disease	Interventional	∙ Drug: 11C-ER176	2	December 2026 (estimated)
NCT04795466	Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer’s Disease	Not yet recruiting	Mild cognitive impairment	Interventional	∙ Biological: Canakinumab	2	July 3, 2023 (estimated)
			Alzheimer’s disease		∙ Other: Placebo
NCT03645226	Gut Microbiota Across Early Stages of Synucleinopathy: From High-Risk Relatives, REM Sleep Behavior Disorder to Early Parkinson’s Disease	Recruiting	REM sleep behavior disorder	Observational	Diagnostic test: Colonoscopy	Not applicable	March 29, 2023
NCT03702816	The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)	Enrolling by invitation	Alzheimer’s disease	Interventional		2	May 31, 2022 (estimated)
			Parkinson’s disease		∙ Drug: GE180 PET scan
			Inflammation
NCT03457493	TSPO-PET for Neuroinflammation in Parkinson’s Disease	Recruiting	Parkinson’s disease	Interventional	∙ Drug: DPA-714-PET/MRI	1–2	March 2022 (estimated)
NCT04066244	Study of Safety and of the Mechanism of BLZ945 in ALS Patients	Recruiting	Amyotrophic lateral sclerosis	Interventional	∙ Drug: BLZ945	2	March 4, 2022 (estimated)
NCT04057807	Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer’s Disease	Recruiting	Alzheimer’s disease	Interventional	∙ Drug: LPS	Early 1	January 2022 (estimated)
NCT04559828	Attenuation of Inflammatory Processes Associated With Alzheimer’s Disease After Consumption of Pomace Olive Oil (ORIVA2)	Recruiting	Alzheimer’s disease	Interventional	∙ Other: Experimental meal	Not applicable	February 28, 2021 (estimated)
NCT02831283	Imaging Inflammation in Alzheimer’s Disease	Enrolling by invitation	Alzheimer’s disease	Interventional	∙ Drug: 11C-PBR28, 18F-Florbetaben	2	June 2021 (estimated)
					∙ Procedure: Lumbar puncture (optional)
NCT02714036	A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)	Completed	Amyotrophic lateral sclerosis	Interventional	∙ Drug: Ibudilast	1 - 2	June 30, 2020 (estimated)
NCT03412604	Effect of Modulating Gamma Oscillations Using tACS	Completed	Alzheimer’s disease	Interventional	∙ Device: Transcranial alternating current stimulation (tACS)	Not applicable	September 15, 2019
NCT03918616	P2×7 Receptor, Inflammation and Neurodegenerative Diseases (NeuroInfiam)	Completed	Neurodegenerative diseases	Observational	∙ Drug: Memantine, dopamine receptor-agonists	Not applicable	March 30, 2019
NCT03548883	Examining Neuroinflammation in AlzHeimer’s (ENHANCE)	Unknown	Alzheimer’s disease, early-onset	Observational	–	Not applicable	December 2018 (estimated)